GlassScriptPhysician profile
Stephanie Thomas
NPI 1003267576
$13,675.48
in general payments reported to CMS, 2019-2025
22 companies · $7,122 in 2025
The $7,122 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $2,885 · 2023: $233 · 2024: $3,240 · 2025: $7,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,150 · Food and Beverage: $1,408 · Travel and Lodging: $38.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,150.00 |
| Food and Beverage | $1,408.07 |
| Travel and Lodging | $38.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,750.01 | 2022-2025 | Da Vinci Surgical System |
| Teva Pharmaceuticals USA, INC. | $140.03 | 2021-2022 | |
| Atricure, INC. | $135.91 | 2024 | |
| Abbvie INC. | $85.91 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.30 | 2025 | |
| Merck Sharp & Dohme LLC | $59.30 | 2023-2024 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $40.96 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.65 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $33.68 | 2022-2023 | Imfinzi |
| Partner Therapeutics, INC. | $32.50 | 2025 | Bizengri |
| Bayer Healthcare Pharmaceuticals INC. | $30.53 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $29.12 | 2021 | |
| Alexion Pharmaceuticals, INC. | $28.44 | 2025 | Ultomiris |
| Novo Nordisk INC | $27.64 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $26.22 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $24.97 | 2023 | |
| Janssen Scientific Affairs, LLC | $24.04 | 2024 | Rybrevant, Talvey, Tecvayli |
| Innovation Technologies INC | $22.96 | 2024 | Irrisept |
| Otsuka America Pharmaceutical, INC. | $22.53 | 2021 | |
| Alon Medical Technology | $20.17 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.91 | 2021 | |
| Lilly USA, LLC | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.